Every engagement begins with a complimentary 30-minute Discovery Call. We listen, scope and agree success criteria before we agree fees. A named senior consultant is assigned from day one — no juniors, no hand-offs.

Our directors, Arunesh Sil and Rod Grundy, lead delivery personally, supported by a curated network of senior associates including Henrik Schou, Barry Daly PhD and Ashley Miller PhD. You always have a single point of accountability.

Yes. ABPI Code thinking is the backbone of everything we do — from materials review and signatory cover to event delivery and field medical content. We have signed, audited and defended materials for some of the largest names in pharma.

Our directors and associates bring deep experience across cardiovascular, diabetes, cGVHD, head and neck oncology and adjacent areas — with a wider associate network for additional specialisms when needed.

Yes. Our flexible model — single project, retained advisory or fractional MSL — is designed to scale with companies at every stage, from emerging biotech through to global pharmaceutical organisations.

No. We work with one client at a time per therapy area. Your strategy stays your strategy.

From kickoff to handover, most engagements run between 6 and 16 weeks, with the option of an ongoing retained advisory relationship for continuity.

Bioveritas Partners is a UK-based consultancy serving pharmaceutical and biotech clients across the UK and Europe.